Page last updated: 2024-08-21

quinazolines and vitamin k 3

quinazolines has been researched along with vitamin k 3 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Li, T; Perez-Soler, R	1
Li, T; Ling, YH; Perez-Soler, R; Zou, Y	1
Aoki, I; Bakalova, R; Getsov, P; Ivanova, D; Lazarova, D; Zhelev, Z	1

Reviews

1 review(s) available for quinazolines and vitamin k 3

Article	Year
Skin toxicities associated with epidermal growth factor receptor inhibitors. Targeted oncology, 2009, Volume: 4, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Head and Neck Neoplasms; Humans; Mice; Pancreatic Neoplasms; Patient Education as Topic; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Vitamin K 3	2009

Article

Year

Skin toxicities associated with epidermal growth factor receptor inhibitors.

Targeted oncology, 2009, Volume: 4, Issue:2

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Head and Neck Neoplasms; Humans; Mice; Pancreatic Neoplasms; Patient Education as Topic; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Vitamin K 3

2009

Other Studies

2 other study(ies) available for quinazolines and vitamin k 3

Article	Year
The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Nov-01, Volume: 17, Issue:21 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Growth Processes; Cetuximab; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Humans; Keratinocytes; Mice; Mice, Inbred ICR; Phosphorylation; Protein Tyrosine Phosphatases; Quinazolines; Reactive Oxygen Species; Skin; Vitamin K 3	2011
Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib. Anticancer research, 2018, Volume: 38, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Ascorbic Acid; Cell Survival; Cells, Cultured; Everolimus; Humans; Jurkat Cells; Leukemia; Lipid Peroxides; Lymphocytes; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Vitamin K 3; Vitamins	2018

Article

Year

The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Nov-01, Volume: 17, Issue:21

Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Growth Processes; Cetuximab; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase; Humans; Keratinocytes; Mice; Mice, Inbred ICR; Phosphorylation; Protein Tyrosine Phosphatases; Quinazolines; Reactive Oxygen Species; Skin; Vitamin K 3

2011

Vitamins C and K3: A Powerful Redox System for Sensitizing Leukemia Lymphocytes to Everolimus and Barasertib.

Anticancer research, 2018, Volume: 38, Issue:3

Topics: Antineoplastic Agents; Apoptosis; Ascorbic Acid; Cell Survival; Cells, Cultured; Everolimus; Humans; Jurkat Cells; Leukemia; Lipid Peroxides; Lymphocytes; Organophosphates; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Vitamin K 3; Vitamins

2018